PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsInsmed
Insmed(INSM)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Plot placeholder
Mock data
Subscribe for the real data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
ArikayceAmikacin2018-09-282024-2035
Respiratory tract infections
,
Urinary tract infections
,
Bacterial infections
,
Intraabdominal infections
,
Pseudomonas infections
,
Infectious skin diseases
,
Escherichia coli infections
,
Soft tissue infections
,
Surgical wound infection
,
Staphylococcal infections
,
Burns
,
Endocarditis
,
Central nervous system infections
,
Proteus infections
,
Infectious bone diseases
,
Acinetobacter infections
,
Klebsiella infections
,
Mycobacterium infections
,
Serratia infections
IplexMecasermin rinfabate2005-12-12
—
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Amikacin
healthy volunteers/patients
,
respiratory aspiration
,
bronchiectasis
,
lung diseases
,
nontuberculous mycobacteria
,
infections
,
cystic fibrosis
,
fibrosis
,
nontuberculous mycobacterium infections
,
mycobacterium infections
,
persistent infection
,
mycobacterium avium-intracellulare infection
,
communicable diseases
,
pseudomonas infections
Mecasermin rinfabate
myotonic dystrophy
,
laron syndrome
,
syndrome
Brensocatib
healthy volunteers/patients
,
renal insufficiency
,
liver diseases
,
hepatic insufficiency
,
fibrosis
,
cystic fibrosis
,
nasal polyps
,
hidradenitis suppurativa
,
bronchiectasis
,
covid-19
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use